Bimatoprost ophthalmic solution in facial vitiligo

Area of Science:

• Dermatology
• Ophthalmology

Background:

• Vitiligo is a common pigmentary disorder resulting from melanocyte destruction.
• Stable facial vitiligo presents a therapeutic challenge.

Purpose of the Study:

• To assess the effectiveness of bimatoprost ophthalmic solution for treating stable facial vitiligo.
• Investigate bimatoprost's potential as a novel treatment for vitiligo.

Main Methods:

• A study involving eight patients with stable facial vitiligo.
• Treatment administered: bimatoprost 0.03% ophthalmic solution, once daily for 12 weeks.
• Evaluation included photographic and dermoscopic assessments at follow-up intervals.

Main Results:

• Excellent repigmentation observed in 50% of cases (4 out of 8).
• Partial repigmentation achieved in 25% of cases (2 out of 8).
• Poor response noted in 25% of cases (2 out of 8).

Conclusions:

• Topical bimatoprost demonstrates potential as a promising treatment for stable vitiligo.
• The preliminary results warrant larger-scale clinical trials to validate efficacy and safety.